Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

GlaxoSmithKline Passes On Option For Exelixis’ XL647 Lung Cancer Candidate

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Exelixis says it will move aggressively to advance EGFR candidate into pivotal trials in first half of 2008 for NSCLC and Phase II for other cancers.

You may also be interested in...



Exelixis, GSK Deal Comes To A ‘Natural, Positive End’

GSK got what it came for, Exelixis’ CEO tells “The Pink Sheet” DAILY.

Exelixis, GSK Deal Comes To A ‘Natural, Positive End’

GSK got what it came for, Exelixis’ CEO tells “The Pink Sheet” DAILY.

GSK Selects Exelixis’ Phase II MET Inhibitor XL880

XL880 is first compound to be selected by GSK under collaboration that allows U.K. drug maker to choose three of 12 Exelixis candidates.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS066377

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By